What is the price target for PROK stock?
15 analysts have analysed PROK and the average price target is 6.63 USD. This implies a price increase of 310.53% is expected in the next year compared to the current price of 1.615.
PROKIDNEY CORP (PROK) Forecast, Price Target & Analyst Ratings
NASDAQ:PROK • US74291D1046
Current stock price
1.615 USD
+0.01 (+0.94%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROKIDNEY CORP (PROK).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.15
- Revenue Estimate
- 168.81K
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.63
Upside
+ 310.53%
From current price of $1.62 to mean target of $6.63, Based on 15 analyst forecasts
Low
$1.01
Median
$7.14
High
$12.60
Price Target Revisions
1 Month
-3.19%
3 Months
-3.19%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for PROK. The average price target is 6.63 USD. This implies a price increase of 310.53% is expected in the next year compared to the current price of 1.615.
The average price target has been revised downward by 3.19% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.67%
PROK was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about PROK.
In the previous month the buy percentage consensus was at a similar level.
PROK was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-16 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-14 | Guggenheim | Maintains | Buy -> Buy |
| 2025-07-09 | Citigroup | Maintains | Buy -> Buy |
| 2025-06-30 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2024-09-30 | JP Morgan | Initiate | Neutral |
| 2024-09-10 | Guggenheim | Initiate | Buy |
| 2024-09-04 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-06-10 | Jefferies | Maintains | Buy -> Buy |
| 2024-05-29 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-01-02 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-07-25 | BTIG | Initiate | Buy |
| 2022-12-21 | Jefferies | Initiate | Buy |
| 2022-11-10 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-10-18 | UBS | Initiate | Buy |
| 2022-10-14 | Citigroup | Initiate | Buy |
| 2022-09-02 | Evercore ISI Group | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.15
- Revenue Estimate
- 168.81K
- Revenue Q2Q
- -26.60%
- EPS Q2Q
- -11.81%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
-17.25%
Revenue (3 Months)
N/A
EPS (1 Month)
-18.75%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 76K | 893K 1,075.00% | 265.2K -70.30% | 331.5K 25.00% | 309.98M 93,408.30% | 159.38M -48.58% | 343.89M 115.77% | 1.263B 267.27% | 1.588B 25.73% | 1.917B 20.72% | ||
| EBITDA YoY % growth | -147.669M 1.53% | -172.92M -17.10% | -158.432M 8.38% | -165.321M -4.35% | -179.595M -8.63% | N/A | -176.868M | -55.59M 68.57% | N/A | N/A | N/A | |
| EBIT YoY % growth | -151.522M 0.97% | -178.352M -17.71% | -165.007M 7.48% | -172.011M -4.24% | -185.231M -7.69% | -82.824M 55.29% | -121.176M -46.31% | -10.761M 91.12% | 268.87M 2,598.56% | 397.39M 47.80% | 527.34M 32.70% | |
| Operating Margin | N/A | -234,673.68% | -18,477.83% | -64,861.03% | -55,876.56% | -26.72% | -76.03% | -3.13% | 21.29% | 25.02% | 27.51% | |
| EPS YoY % growth | -0.57 51.54% | -0.63 -10.53% | -0.52 17.46% | -0.50 4.04% | -0.49 2.62% | -0.36 26.53% | -0.34 5.71% | 0.20 160.61% | 0.15 -25.00% | 0.41 166.67% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.15 -11.81% | -0.15 -14.36% | -0.15 -28.56% | -0.16 -17.30% | -0.15 -5.26% | -0.11 24.53% | -0.11 27.27% | -0.11 31.68% |
| Revenue Q2Q % growth | 168.81K -26.60% | 168.81K -23.62% | 168.81K -22.21% | 168.81K -24.97% | 204K 20.85% | 204K 20.85% | 204K 20.85% | 204K 20.85% |
| EBITDA Q2Q % growth | -45.459M -14.25% | -46.207M -26.10% | -47.01M -39.08% | -47.871M -23.39% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -47.402M -14.53% | -48.218M -21.43% | -49.059M -27.30% | -49.674M -9.48% | -49.776M -5.01% | -47.022M 2.48% | -45.39M 7.48% | -47.532M 4.31% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
9.51%
EPS Next 5 Year
19.06%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
616.21%
Revenue Next 5 Year
232.69%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
10.56%
PROKIDNEY CORP / PROK Forecast FAQ
What are the consensus estimates for PROKIDNEY CORP (PROK) next earnings?
The consensus EPS estimate for the next earnings of PROKIDNEY CORP (PROK) is -0.15 USD and the consensus revenue estimate is 168.81K USD.
What is the expected long term growth rate for PROKIDNEY CORP (PROK)?
The expected long term growth rate for PROKIDNEY CORP (PROK) is 616.21%.